Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors

被引：0
|
作者：
Castello, A. [1 ]
Rossi, S. [1 ]
Toschi, L. [1 ]
Lopci, E. [1 ]
机构：
[1] Humanitas Clin & Res Hosp, Rozzano, MI, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-024
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [41] Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).
    Lau, Sally C. M.
    Le, Lisa W.
    Smith, Elliot Charles
    Chan, Sze Wah Samuel
    Ryan, Malcolm
    Brown, M. Catherine
    Hueniken, Katrina
    Eng, Lawson
    Patel, Devalben
    Chen, RuiQi
    Sung, Mike Ru
    Zer, Alona
    Bradbury, Penelope Ann
    Ohashi, Pamela S.
    Shepherd, Frances A.
    Tsao, Ming Sound
    Liu, Geoffrey
    Leighl, Natasha B.
    Sacher, Adrian G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?
    Gray, Steven G.
    Cuffe, Sinead
    Finn, Stephen P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : E142 - E144
  • [43] Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
    Taoka, Masataka
    Ochi, Nobuaki
    Yamane, Hiromichi
    Yamamoto, Takenobu
    Kawahara, Tatsuyuki
    Uji, Emiko
    Kosaka, Youko
    Takeda, Kouhei
    Nagasaki, Yasunari
    Nakanishi, Hidekazu
    Aoyama, Yumi
    Takigawa, Nagio
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (03) : 456 - 462
  • [44] Prognostic value of serum proteomic signature in NSCLC patients on immune checkpoint inhibitors: Impact of treatment regimen and PD-L1 levels
    Kim, Leeseul
    Um, Taegyu
    Chae, Young Kwang
    Cho, Allen
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
    Wang, Yimin
    Han, Hedong
    Zhang, Fang
    Lv, Tangfeng
    Zhan, Ping
    Ye, Mingxiang
    Song, Yong
    Liu, Hongbing
    BRITISH JOURNAL OF CANCER, 2022, 127 (05) : 948 - 956
  • [46] Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
    Abdel-Rahman, Omar
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 101 : 75 - 85
  • [47] PD-L1 as a biomarker of response to immune-checkpoint inhibitors
    Deborah Blythe Doroshow
    Sheena Bhalla
    Mary Beth Beasley
    Lynette M. Sholl
    Keith M. Kerr
    Sacha Gnjatic
    Ignacio I. Wistuba
    David L. Rimm
    Ming Sound Tsao
    Fred R. Hirsch
    Nature Reviews Clinical Oncology, 2021, 18 : 345 - 362
  • [48] Prognosis value of circulating tumor cell PD-L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum-containing drugs
    Su, Xiaona
    Zhou, Ci
    Chen, Shu
    Ma, Qiang
    Xiao, He
    Chen, Qian
    Zou, Hua
    ONCOLOGY LETTERS, 2024, 27 (03)
  • [49] PD-L1 as a biomarker of response to immune-checkpoint inhibitors
    Doroshow, Deborah Blythe
    Bhalla, Sheena
    Beasley, Mary Beth
    Sholl, Lynette M.
    Kerr, Keith M.
    Gnjatic, Sacha
    Wistuba, Ignacio I.
    Rimm, David L.
    Tsao, Ming Sound
    Hirsch, Fred R.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (06) : 345 - 362
  • [50] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345